Abstract 3564
Background
The therapeutic landscape for mUC is rapidly evolving, with the introduction of immune checkpoint inhibitors (CPIs) and targeted therapies providing new options. Prognostic and predictive biomarkers are urgently needed to facilitate clinical decision-making. In this setting, ctDNA is a non-invasive method for genomic profiling, but its clinical utility remains largely untested.
Methods
Whole blood samples were collected for next-generation sequencing of leukocyte and cell-free DNA (cfDNA). Deep targeted sequencing was performed across a UC-specific custom 50-gene panel to a median unique read depth of 1040x for cfDNA. Clinical records were reviewed for baseline characteristics and outcomes.
Results
From 12/2014 until 11/2018, 103 patients with mUC underwent blood collection for cfDNA analysis. Of these, 84 had detectable ctDNA. Baseline characteristics and outcomes are presented in the table below for the entire cohort, along with exploratory analyses for patients who received platinum-based chemotherapy or a CPI in the metastatic setting. For cases with ctDNA>1%, selected results based on the presence or absence of mutations (muts.) in TP53 and ERCC2, as well as tumour mutation burden (TMB), are included.Table:
934P
All cases (N = 103) | |||
---|---|---|---|
Median age (range) | 67 (37-88) | ||
Male (%) | 83 | ||
Smoker (%) | 63 | ||
Median ctDNA (%) | 15.7 | ||
Median overall survival (OS, months) | Present | Absent | P-value |
ctDNA > median | 6.2 | 15.7 | 0.018 |
TP53 mut. | 16.9 | 27.1 | 0.082 |
ERCC2 mut. | 31.6 | 19.6 | 0.097 |
Platinum-treated (N = 54) | |||
Carboplatin (%) | 37 | ||
First-line (%) | 89 | ||
Median progression-free survival (PFS, months) | Present | Absent | P-value |
TP53 mut. | 6.0 | 6.7 | 0.76 |
ERCC2 mut. | 13.4 | 5.5 | 0.028 |
CPI-treated (N = 50) | |||
Combination with CTLA-4 (%) | 10 | ||
First-line (%) | 54 | ||
Median PFS (months) | Present | Absent | P-value |
TP53 mut. | 3.3 | 3.2 | 0.92 |
ERCC2 mut. | 2.9 | 3.3 | 0.22 |
TMB > 25 mut./Mb | 4.4 | 2.9 | 0.67 |
Conclusions
In our mUC cohort, the presence of ctDNA fraction above median correlated with worse OS, while mutations in ERCC2 correlated with improved PFS for platinum-treated patients. These data support the further exploration and validation of ctDNA as a tool for biomarker development in mUC. Additional analyses will be presented for the entire 50-gene panel.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Canadian Institutes of Health Research (CIHR) Bladder Cancer Canada (BCC).
Disclosure
J. Lavoie: Honoraria (self): Astellas. N.L. Sundahl: Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: BMS. D. Khalaf: Advisory / Consultancy: Bayer. T. Todenhöfer: Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: BMS. C.K. Kollmannsberger: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Eisai; Honoraria (self), Advisory / Consultancy: Ipsen; Advisory / Consultancy: Janssen; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Roche. K.N. Chi: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Essa; Advisory / Consultancy: Amgen; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Roche; Research grant / Funding (institution): Tokai Pharmaceuticals; Research grant / Funding (institution): Lilly/ImClone; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Merck. B.J. Eigl: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Zomanex; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Research grant / Funding (institution): Astellas; Honoraria (self), Research grant / Funding (institution): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
3117 - A modified Edmonton Symptom Assessment Scale for assessing symptoms in one day chemotherapy clinic
Presenter: Anjuleta Kampitsi
Session: Poster Display session 3
Resources:
Abstract
6058 - Level of physical activity and nutritional status in cancer patients with fatigue: an exploratory cross-sectional study
Presenter: Patrick Jahn
Session: Poster Display session 3
Resources:
Abstract
1980 - Catheter related necrotizing fascitiis in haematological patients. Case report and implications for nursing
Presenter: Arianna Rosich Soteras
Session: Poster Display session 3
Resources:
Abstract
3984 - Everyday life with Long-term Chemotherapy Induced Peripheral Neuropathy among Patient in Adjuvant Treatment for Colorectal Cancer – a Multi Methods Study
Presenter: Marlene Jensen
Session: Poster Display session 3
Resources:
Abstract
2202 - Scalp cooler is effective in reducing chemotherapy-induced alopecia among breast cancer patients : a single institution experience
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
5942 - Nursing management of fatigue in cancer patients: mixed methods study
Presenter: Angela Tolotti
Session: Poster Display session 3
Resources:
Abstract
2930 - Awareness of Nursing Students about the Warning Signs of Cancer
Presenter: Hatice Yakar
Session: Poster Display session 3
Resources:
Abstract
2978 - Assessment of quality of life in patients with cancer and diabetes 2 in Northern Greece.
Presenter: STYLIANI MICHALOPOULOU
Session: Poster Display session 3
Resources:
Abstract
3400 - Radiation dose variables related to the causes of skin toxicities in women with breast cancer: a study proposal
Presenter: EULALIA PUJOL
Session: Poster Display session 3
Resources:
Abstract
2156 - How should the symptoms be managed after breast cancer surgery? An example of mobile app
Presenter: AYDANUR AYDIN
Session: Poster Display session 3
Resources:
Abstract